Clinical Trial Update: Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a five-drug combination (lenalidomide, rituximab, gemcitabine, oxaliplatin, dexamethasone) for relapsed or refractory diffuse …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Decadron (Dexamethasone)
• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 1 | Status: UNKNOWN